Published in Am J Gastroenterol on November 01, 2012
Functional bowel disorders. Gastroenterology (2006) 20.72
Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet (2000) 10.36
Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med (2011) 10.03
A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med (2001) 3.05
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol (2012) 2.90
Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol (2006) 2.71
Two randomized trials of linaclotide for chronic constipation. N Engl J Med (2011) 2.14
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol (2012) 2.11
Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther (2008) 2.06
Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res (1998) 1.94
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 1.94
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol (2010) 1.74
Efficacy of linaclotide for patients with chronic constipation. Gastroenterology (2010) 1.71
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther (1999) 1.66
Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology (2010) 1.61
Patient-reported outcomes for irritable bowel syndrome are associated with patients' severity ratings of gastrointestinal symptoms and psychological factors. Clin Gastroenterol Hepatol (2011) 1.48
Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol (2011) 1.47
Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci (2010) 1.42
Measuring successful treatment of irritable bowel syndrome: is "satisfactory relief " enough? Am J Gastroenterol (2006) 1.18
Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology (2009) 1.11
Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. Aliment Pharmacol Ther (2010) 0.97
Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice. Aliment Pharmacol Ther (2010) 0.89
The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies. Drug Saf (2011) 0.88
Tegaserod and ischemic colitis. N Engl J Med (2004) 0.88
Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther (2006) 0.86
Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother (2012) 0.81
End points in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol (2011) 0.77
Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol (2014) 2.11
Long-term therapeutic outcome of patients undergoing ambulatory pH monitoring for chronic unexplained cough. J Clin Gastroenterol (2010) 1.90
Clinical recognition of Al type amyloidosis of the luminal gastrointestinal tract. Clin Gastroenterol Hepatol (2007) 1.88
Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care (2007) 1.57
Learners favour high resolution oesophageal manometry with better diagnostic accuracy over conventional line tracings. Gut (2011) 1.33
Abnormal GERD parameters on ambulatory pH monitoring predict therapeutic success in noncardiac chest pain. Am J Gastroenterol (2009) 1.21
Polysymptomatic, polysyndromic presentation of patients with urological chronic pelvic pain syndrome. J Urol (2012) 1.04
Efficacy of sertraline in prevention of depression recurrence in older versus younger adults with diabetes. Diabetes Care (2007) 0.98
Zonisamide or levetiracetam for adults with cyclic vomiting syndrome: a case series. Clin Gastroenterol Hepatol (2006) 0.93
Brunner gland cyst: report of three cases. Int J Clin Exp Pathol (2008) 0.87
The effect of antisecretory therapy and study duration on ambulatory esophageal pH monitoring. Dig Dis Sci (2010) 0.85
Identification of a functional TPH1 polymorphism associated with irritable bowel syndrome bowel habit subtypes. Am J Gastroenterol (2013) 0.84
Gastroesophageal reflux symptoms in 9/11 survivors and workers: insights gained from tragic losses. Am J Gastroenterol (2011) 0.82
Sensory neuromodulators in functional nausea and vomiting: predictors of response. Postgrad Med J (2012) 0.80
Antidepressant pharmacotherapy in adults with type 2 diabetes: rates and predictors of initial response. Diabetes Care (2009) 0.80
Defining optimal therapeutic outcomes in chronic hepatitis. Arch Med Res (2007) 0.76
Resect and discard approach to colon polyps: real-world applicability among academic and community gastroenterologists. Dig Dis Sci (2014) 0.76
Liver volume in the cirrhotic patient: does size matter? Dig Dis Sci (2014) 0.75
Witnessed versus unwitnessed random urine tests in the treatment of opioid dependence. Am J Addict (2013) 0.75
Correction: IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype. PLoS One (2015) 0.75
Ray E. Clouse, MD, Washington University gastroenterologist, clinical investigator, and educator. Gastroenterology (2007) 0.75
Corrigendum: Impact of Retroflexion Vs. Second Forward View Examination of the Right Colon on Adenoma Detection: A Comparison Study. Am J Gastroenterol (2015) 0.75